Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) P2RY2 Antibodies:
anti-Human P2RY2 Antibodies:
anti-Rat (Rattus) P2RY2 Antibodies:
Go to our pre-filtered search.
Human Polyclonal P2RY2 Primary Antibody for IHC (p), IHC - ABIN2801830
Zaika, Zhang, Shapiro: Functional role of M-type (KCNQ) K⁺ channels in adrenergic control of cardiomyocyte contraction rate by sympathetic neurons. in The Journal of physiology 2011
Human Polyclonal P2RY2 Primary Antibody for IF (p), IHC (p) - ABIN755008
Liu, Kong, Jin, Gao, Qu, Zheng: Expression of the P2Y2 receptor in the terminal rectum of fetal rats with anorectal malformation. in International journal of clinical and experimental medicine 2015
knockdown of P2Y2R retarded cyst expansion in vitro and prevented ATP- and HIF-1alpha (show HIF1A Antibodies)-dependent cyst growth. In conclusion, P2Y2R mediates ATP-dependent cyst growth and is transcriptionally regulated by HIF-1alpha (show HIF1A Antibodies).
P2Y2R is an inhibitor of arterial intimal calcification, regulating the osteoblastic trans-differentiation of smooth muscle cells through P2Y2R-mediated Runx2 (show RUNX2 Antibodies) antagonism.
These findings are consistent with the notion that the primary action of P2Y2 receptor signalling in bone is to regulate extracellular ATP levels.
Results demonstrate that P2Y2 contributes to response properties of cutaneous afferents, as P2Y2 deletion reduces responsiveness of conventional unmyelinated polymodal afferents to heat and appears to result in the acquisition of mechanical responsiveness in a subset of TRPV1 (show TRPV1 Antibodies)-expressing afferents.
This study suggests that P2Y2 may participate in cardiomyopathy in mdx (show DMD Antibodies) mice.
Extracellular ATP induces vascular inflammation and atherosclerosis via activation of P2Y2.
Endothelial cell-specific P2Y2R deficiency reduces atherosclerotic burden and promotes plaque stability in ApoE (show APOE Antibodies)(-/-) mice through impaired macrophage infiltration acting together with reduced matrix metalloproteinase-2 (show MMP2 Antibodies) activity and increased smooth muscle cell migration.
expression of P2Y (show P2RY1 Antibodies)(2) receptor in peripheral sensory neurons that innervate the injured tissue and the activation of P2Y (show P2RY1 Antibodies) receptors contributes to mechanical allodynia following inflammation
In P2Y1R (-/-) mice, the expression of P2Y2 receptor in muscle was reduced by over 50 %, as compared to P2Y1R (+/+) mice.
P2Y2R deficiency does not alter baseline collateral vessel formation but does significantly impair collateral maturation, with resultant persistent limb ischemia despite enhanced angiogenesis.
Human umbilical vein endothelial cells exposed to either P2Y2 receptor antagonists or siRNA showed impaired fluid shear stress-induced cell alignment, and actin stress fiber formation as early as 6 h.
There is increased expression of P2Y2 receptors in the rectosigmoid mucosa of diarrhea-predominant irritable bowel syndrome patients. P2Y2 correlated with abdominal pain.
A novel SNP-systemic lupus erythematosus association was identified between FCHSD2 and P2RY2, peaking at rs11235667 on a 33-kb haplotype upstream of ATG16L2.
Hypoxia and upregulated HIF-1a (show HIF1A Antibodies) both upregulated the P2Y2 levels in hepatocellular carcinoma cells and increased their survival.
Results show that purinergic receptor P2Y2 (P2Y2R) requires N-glycosylation for expression on the cell surface.
Data indicate that knockdown of caveolin-1 (Cav-1 (show CAV1 Antibodies)) expression causes redistribution of the P2Y2 nucleotide receptor (P2Y2R) from membrane rafts.
The P2RY2 receptor induces carcinoma cell migration and epithelial-mesenchymal transition through cross-talk with EGFR (show EGFR Antibodies).
Activation of P2Y2R increased TF promoter activity and mRNA expression in coronary artery endothelial cells.
Data show that the purinergic receptor P2Y2 (P2Y2R) pepducin activates neutrophils through formyl peptide receptor 2 (FPR2 (show FPR2 Antibodies)), and ATP is turned into an activating agonist through a receptor cross-talk mechanism that involves both FPR2 (show FPR2 Antibodies) and P2Y2R.
P2Y2 receptor and EGFR (show EGFR Antibodies) cooperate to promote prostate cancer cell invasion via ERK1/2 (show MAPK1/3 Antibodies) pathway.
P2Y2 and Gq/G11 (show STK19 Antibodies) are required for basal endothelial NO formation, vascular tone, and blood pressure.
the effect of ATP on Na+-ATPase (show DNAH8 Antibodies) activity could be involved in antinatriuresis induced by P2Y4 receptor (show P2RY4 Antibodies) or a mechanism to counterbalance the natriuretic effect of P2Y2 receptor, promoting fine control of sodium reabsorption in proximal tubule cells.
The product of this gene belongs to the family of P2 receptors, which is activated by extracellular nucleotides and subdivided into P2X ligand-gated ion channels and P2Y G-protein coupled receptors. This family has several receptor subtypes with different pharmacological selectivity, which overlaps in some cases, for various adenosine and uridine nucleotides. This receptor, found on many cell types, is activated by ATP and UTP and is reported to be overexpressed on some cancer cell types. It is involved in many cellular functions, such as proliferation, apoptosis and inflammation. Three transcript variants encoding the same protein have been identified for this gene.
P2Y purinoceptor 2
, ATP receptor
, P2U purinoceptor 1
, P2U nucleotide receptor
, P2U receptor 1
, purinergic receptor P2Y2
, purinoceptor P2Y2
, P2Y ATP receptor 2
, P2Y2 nucleotide receptor